- Home
- GH
as of 02-06-2026 4:00pm EST
$101.85
+$3.49
+3.55%
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 14.8B | IPO Year: | 2018 |
| Target Price: | $102.81 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $34.88 - $120.74 | Next Earning Date: | 02-19-2026 |
| Revenue: | $902,569,000 | Revenue Growth: | 30.38% |
| Revenue Growth (this year): | 35.23% | Revenue Growth (next year): | 27.38% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -262233000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
Monroe Terilyn J.
Sell
Chief People Officer
GH Jan 21, 2026
Avg Cost/Share
$113.84
Shares
8,571
Total Value
$977,901.82
Owned After
20,990
Monroe Terilyn J.
Sell
Chief People Officer
GH Jan 7, 2026
Avg Cost/Share
$112.60
Shares
10,031
Total Value
$1,124,279.50
Owned After
20,990
Tariq Musa
Sell
Director
GH Dec 17, 2025
Avg Cost/Share
$101.46
Shares
116
Total Value
$11,769.36
Owned After
7,993
SEC Form 4
Chudova Darya
Sell
Chief Technology Officer
GH Dec 15, 2025
Avg Cost/Share
$104.04
Shares
5,451
Total Value
$567,131.85
Owned After
7,012
SEC Form 4
Eltoukhy Helmy
Sell
Co-Chief Executive Officer
GH Dec 15, 2025
Avg Cost/Share
$103.91
Shares
90,565
Total Value
$9,402,220.02
Owned After
2,053,763
Kalia Kumud
Sell
Chief Information Officer
GH Dec 8, 2025
Avg Cost/Share
$104.60
Shares
2,000
Total Value
$209,204.20
Owned After
22,365
SEC Form 4
Chudova Darya
Sell
Chief Technology Officer
GH Dec 8, 2025
Avg Cost/Share
$105.52
Shares
22,935
Total Value
$2,417,979.82
Owned After
7,012
Talasaz AmirAli
Sell
Co-Chief Executive Officer
GH Dec 8, 2025
Avg Cost/Share
$105.18
Shares
100,000
Total Value
$10,505,473.54
Owned After
168,223
Hidalgo Medina Manuel
Sell
Director
GH Dec 8, 2025
Avg Cost/Share
$105.00
Shares
1,250
Total Value
$131,250.00
Owned After
797
Monroe Terilyn J.
Sell
Chief People Officer
GH Dec 1, 2025
Avg Cost/Share
$106.40
Shares
55,167
Total Value
$5,846,163.49
Owned After
20,990
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Monroe Terilyn J. | GH | Chief People Officer | Jan 21, 2026 | Sell | $113.84 | 8,571 | $977,901.82 | 20,990 | |
| Monroe Terilyn J. | GH | Chief People Officer | Jan 7, 2026 | Sell | $112.60 | 10,031 | $1,124,279.50 | 20,990 | |
| Tariq Musa | GH | Director | Dec 17, 2025 | Sell | $101.46 | 116 | $11,769.36 | 7,993 | |
| Chudova Darya | GH | Chief Technology Officer | Dec 15, 2025 | Sell | $104.04 | 5,451 | $567,131.85 | 7,012 | |
| Eltoukhy Helmy | GH | Co-Chief Executive Officer | Dec 15, 2025 | Sell | $103.91 | 90,565 | $9,402,220.02 | 2,053,763 | |
| Kalia Kumud | GH | Chief Information Officer | Dec 8, 2025 | Sell | $104.60 | 2,000 | $209,204.20 | 22,365 | |
| Chudova Darya | GH | Chief Technology Officer | Dec 8, 2025 | Sell | $105.52 | 22,935 | $2,417,979.82 | 7,012 | |
| Talasaz AmirAli | GH | Co-Chief Executive Officer | Dec 8, 2025 | Sell | $105.18 | 100,000 | $10,505,473.54 | 168,223 | |
| Hidalgo Medina Manuel | GH | Director | Dec 8, 2025 | Sell | $105.00 | 1,250 | $131,250.00 | 797 | |
| Monroe Terilyn J. | GH | Chief People Officer | Dec 1, 2025 | Sell | $106.40 | 55,167 | $5,846,163.49 | 20,990 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
📊
AI Sentiment
Positive
6/10
Simply Wall St.
Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Merck Reshapes Oncology Strategy With Partnerships While Shares Screen As Undervalued
📊
AI Sentiment
Positive
7/10
MT Newswires
UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating
📈
AI Sentiment
Highly Positive
8/10
Compare GH vs Leading Stocks
See how GH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.